CI-GBHC@EC2605A(17918.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
CI-GBHC@EC2605A
17918.HK
News
View More

Morning Trend | GIANT BIOGENE Bullish Confidence Wavers, Key Support at Risk?

On January 27th, GIANT BIOGENE (2367.HK) experienced weak fluctuations during the trading session, repeatedly testing the support at the 28 yuan mark without success. Throughout the day, funds continued to flow out, with a high proportion of trading occurring in the red, indicating a gradual loss of confidence among bulls, and the main positions began to loosen. The biotechnology sector has shown continued weakness over the past week due to differences in local policies. The sector's funds are extremely cautious, lacking leadership from major companies, making it difficult to ignite a bullish atmosphere in the short term. GIANT BIOGENE has not released any significant announcements recently, and the valuation support story struggles to attract new followers. The overall industry sentiment is low, with funds only able to switch between localized hotspots, leading to a further contraction in risk appetite. Technically, indicators such as MACD, KDJ, and RSI have all weakened, and a clear downward channel has formed on the daily chart. Although there have been occasional attempts by the main players to bottom-fish in the short term, there are no signs of an overall trend reversal, with the dominance of funds leaning more towards the bears. If there are active large orders that can reverse the trend in the intraday session, there may be a turning point; otherwise, the weak consolidation is likely to continue. In summary, GIANT BIOGENE is currently in a phase of dissipating bullish confidence. If the key support level of 28 yuan is breached, it may trigger a new round of technical sell-off. It is recommended that investors focus on position control, wait for unusual fund movements and intraday improvement signals, and avoid blindly betting on a rebound from the left side

Technical Forecast·
SZ
159837
-0.39%
HK
02367
-0.88%
SZ
159849
0.00%
Technical Forecast·
SZ
159837
-0.39%
HK
02367
-0.88%
SZ
159849
0.00%

Giant Biogene Holding Insider Ups Holding During Year

Giant Biogene Holding Co., Ltd. (HKG:2367) saw net insider buying over the past year, with Chief Scientific Officer Daidi Fan being the largest buyer, purchasing HK$2.5 billion worth of shares. Despite a significant sale of HK$2.3 billion by Fan, it occurred above the current share price of HK$33.84. Insiders own 55% of the company, valued at approximately HK$20 billion, indicating alignment with shareholders. While no transactions occurred in the last three months, the overall insider activity suggests optimism for the company's future.

Simplywall·
SZ
159837
-0.39%
SZ
159849
0.00%
HK
02367
-0.88%
Simplywall·
SZ
159837
-0.39%
SZ
159849
0.00%
HK
02367
-0.88%

Jefferies Adjusts Giant Biogene's Price Target to HK$50 From HK$55, Keeps at Buy

Jefferies Adjusts Giant Biogene's Price Target to HK$50 From HK$55, Keeps at Buy

marketscreener·
HK
02367
-0.88%
SZ
159837
-0.39%
SH
516500
-0.46%
marketscreener·
HK
02367
-0.88%
SZ
159837
-0.39%
SH
516500
-0.46%

Giant Biogene Wins China Approval for World-First Collagen–Hyaluronate Skin Implant

Giant Biogene Holding Co. Ltd. has received approval in China for its Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Composite Solution, the first of its kind for intradermal injection aimed at improving cheek smoothness. This product enhances the company's collagen portfolio and is expected to create new market opportunities in skin rejuvenation. The current analyst rating for Giant Biogene's stock (HK:2367) is a Hold with a price target of HK$39.50.

Tip Ranks·
HK
02367
-0.88%
Tip Ranks·
HK
02367
-0.88%

Giant Biogene Holding Co. Ltd. (2367) Receives a Buy from Guotai Haitong

Guotai Haitong analyst maintained a Buy rating on Giant Biogene Holding Co. Ltd. yesterday and set a price target of HK$43.60.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The word on The Street in general, suggests a Strong Buy analyst consensus rating for Giant Biogene Holding Co. Ltd. with a HK$52.50 average price target.

Tip Ranks·
HK
02367
-0.88%
Tip Ranks·
HK
02367
-0.88%
Posts
View More

$MAO GEPING(01318.HK) feels like it's not that hot, will check the excess multiple later $GIANT BIOGENE(02367.HK)

  • 0
© 2026 Longbridge｜Disclaimer